These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
650 related articles for article (PubMed ID: 30236106)
1. Progression-specific genes identified in microdissected formalin-fixed and paraffin-embedded tissue containing matched ductal carcinoma in situ and invasive ductal breast cancers. Schultz S; Bartsch H; Sotlar K; Petat-Dutter K; Bonin M; Kahlert S; Harbeck N; Vogel U; Seeger H; Fehm T; Neubauer HJ BMC Med Genomics; 2018 Sep; 11(1):80. PubMed ID: 30236106 [TBL] [Abstract][Full Text] [Related]
2. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308 [TBL] [Abstract][Full Text] [Related]
4. Role of deregulated microRNAs in breast cancer progression using FFPE tissue. Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687 [TBL] [Abstract][Full Text] [Related]
5. Gene Expression Differences between Ductal Carcinoma in Situ with and without Progression to Invasive Breast Cancer. Doebar SC; Sieuwerts AM; de Weerd V; Stoop H; Martens JWM; van Deurzen CHM Am J Pathol; 2017 Jul; 187(7):1648-1655. PubMed ID: 28634007 [TBL] [Abstract][Full Text] [Related]
6. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma. Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525 [TBL] [Abstract][Full Text] [Related]
7. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer. Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755 [TBL] [Abstract][Full Text] [Related]
8. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Knudsen ES; Ertel A; Davicioni E; Kline J; Schwartz GF; Witkiewicz AK Breast Cancer Res Treat; 2012 Jun; 133(3):1009-24. PubMed ID: 22134623 [TBL] [Abstract][Full Text] [Related]
9. Multi-omic profiling of simultaneous ductal carcinoma in situ and invasive breast cancer. Kaplan HG; Dowdell AK; Berry AB; Shimol RB; Robinson FL; Carney CA; Piening BD Breast Cancer Res Treat; 2024 Jun; 205(3):451-464. PubMed ID: 38523186 [TBL] [Abstract][Full Text] [Related]
10. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453 [TBL] [Abstract][Full Text] [Related]
11. Loss of heterozygosity analyses of asynchronous lesions of ductal carcinoma in situ and invasive ductal carcinoma of the human breast. Amari M; Moriya T; Ishida T; Harada Y; Ohnuki K; Takeda M; Sasano H; Horii A; Ohuchi N Jpn J Clin Oncol; 2003 Nov; 33(11):556-62. PubMed ID: 14711979 [TBL] [Abstract][Full Text] [Related]
12. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer. Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987 [TBL] [Abstract][Full Text] [Related]
13. Oestrogen-induced genes in ductal carcinoma in situ: their comparison with invasive ductal carcinoma. Ebata A; Suzuki T; Takagi K; Miki Y; Onodera Y; Nakamura Y; Fujishima F; Ishida K; Watanabe M; Tamaki K; Ishida T; Ohuchi N; Sasano H Endocr Relat Cancer; 2012 Aug; 19(4):485-96. PubMed ID: 22569827 [TBL] [Abstract][Full Text] [Related]
14. Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics. Hulahan TS; Spruill L; Wallace EN; Park Y; West RB; Marks JR; Hwang ES; Drake RR; Angel PM Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928454 [TBL] [Abstract][Full Text] [Related]
15. Robustness of biomarker determination in breast cancer by RT-qPCR: impact of tumor cell content, DCIS and non-neoplastic breast tissue. Hartmann K; Schlombs K; Laible M; Gürtler C; Schmidt M; Sahin U; Lehr HA Diagn Pathol; 2018 Oct; 13(1):83. PubMed ID: 30342538 [TBL] [Abstract][Full Text] [Related]
16. PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma. Sakr RA; Weigelt B; Chandarlapaty S; Andrade VP; Guerini-Rocco E; Giri D; Ng CK; Cowell CF; Rosen N; Reis-Filho JS; King TA Clin Cancer Res; 2014 May; 20(9):2326-37. PubMed ID: 24634376 [TBL] [Abstract][Full Text] [Related]
17. Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS). Geradts J; Groth J; Wu Y; Jin G Breast Cancer Res Treat; 2016 Jun; 157(3):447-59. PubMed ID: 27250000 [TBL] [Abstract][Full Text] [Related]
18. Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. Rohan TE; Ginsberg M; Wang Y; Couch FJ; Feigelson HS; Greenlee RT; Honda S; Stark A; Chitale D; Wang T; Xue X; Oktay MH; Sparano JA; Loudig O BMJ Open; 2021 Oct; 11(10):e053397. PubMed ID: 34702732 [TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation in ductal carcinoma in situ of the male breast. Vermeulen MA; van Deurzen CHM; Doebar SC; de Leng WWJ; Martens JWM; van Diest PJ; Moelans CB Endocr Relat Cancer; 2019 Jun; 26(6):575-584. PubMed ID: 30921768 [TBL] [Abstract][Full Text] [Related]
20. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Park K; Han S; Kim HJ; Kim J; Shin E Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]